Anti-tumor effects of a tumor cell vaccine expressing a membrane-bound form of the IL-12 p35 subunit

Cancer Biology and Therapy

Volumn 10, Issue 4, 2010, Pages 336-343

  Lim, Ho Yong ^a   Ju, Hee Young ^b   Chung, Hee Yong ^c   Kim, Young Sang ^a  

^a Chungnam National University   (South Korea)

^b Daejeon Science High School   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

Anti tumor immunity; CD69; Cytotoxic T lymphocytes; Direct priming; IFN ; IL 12; Membrane bound form; p35 subunit; p40 subunit

Indexed keywords

CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12P35; INTERLEUKIN 12P40; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR ALPHA; CANCER VACCINE; HYBRID PROTEIN; LECTIN; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; FIBROSARCOMA; GENE TRANSFER; GENETIC TRANSFECTION; GROWTH RATE; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FIBROSARCOMA; FLOW CYTOMETRY; GENETIC ENGINEERING; INTERFERON-GAMMA; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKIN-12 SUBUNIT P40; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957133765     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.4.12310     Document Type: Article

References (48)

1. Wong HL, Wilson DE, Jenson JC, Familletti PC, Stremlo DL, Gately MK. Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell Immunol 1988; 111:39-54.
2. Gately MK, Wilson DE, Wong HL. Synergy between recombinant interleukin 2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro. J Immunol 1986; 136:1274-82.
3. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170:827-45.
4. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260:547-9.
5. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, Romagnani S. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177:1199-204. (Pubitemid 23097410)
6. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991; 147:874-82.
7. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998; 70:83-243.
8. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46. (Pubitemid 37328691)
9. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH. Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 2007; 7:1705-21.
10. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, et al. Recombinant IL-12 administration induces tumor regression in association with IFNgamma production. J Immunol 1994; 153:1697-706.
11. Yu WG, Yamamoto N, Takenaka H, Mu J, Tai XG, Zou JP, et al. Molecular mechanisms underlying IFNgamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int Immunol 1996; 8:855-65.
12. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87:581-6.
13. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992; 176:1387-98.
14. Schoenhaut DS, Chua AO, Wolitzky AG, Quinn PM, Dwyer CM, McComas W, et al. Cloning and expression of murine IL-12. J Immunol 1992; 148:3433-40.
15. Fan X, Sibalic V, Niederer E, Wuthrich RP. The proinflammatory cytokine interleukin-12 occurs as a cell membrane-bound form on macrophages. Biochem Biophys Res Commun 1996; 225:1063-7. (Pubitemid 26319227)
16. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991; 146:3074-81.
17. Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu CY, et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA 1996; 93:14002-7.
18. Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: a review. Toxicol Pathol 1999; 27:58-63.
19. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3:409-17.
20. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997; 90:2541-8.
21. Zhang S, Wang Q. Factors determining the formation and release of bioactive IL-12: regulatory mechanisms for IL-12p70 synthesis and inhibition. Biochem Biophys Res Commun 2008; 372:509-12.
22. Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 1995; 154:116-27.
23. Heinzel FP, Hujer AM, Ahmed FN, Rerko RM. In vivo production and function of IL-12 p40 homodimers. J Immunol 1997; 158:4381-8.
24. Gillessen S, Carvajal D, Ling P, Podlaski FJ, Stremlo DL, Familletti PC, et al. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol 1995; 25:200-6.
25. Mattner F, Fischer S, Guckes S, Jin S, Kaulen H, Schmitt E, et al. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol 1993; 23:2202-8.
26. Jana M, Dasgupta S, Saha RN, Liu X, Pahan K. Induction of tumor necrosis factor-alpha (TNFalpha) by interleukin-12 p40 monomer and homodimer in microglia and macrophages. J Neurochem 2003; 86:519-28. (Pubitemid 36842451)
27. Jana M, Pahan K. IL-12 p40 homodimer, but not IL-12 p70, induces the expression of IL-16 in microglia and macrophages. Mol Immunol 2009; 46:773-83.
28. Cooper AM, Khader SA. IL-12p40: an inherently agonistic cytokine. Trends Immunol 2007; 28:33-8.
29. Khader SA, Partida-Sanchez S, Bell G, Jelley-Gibbs DM, Swain S, Pearl JE, et al. Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J Exp Med 2006; 203:1805-15.
30. Marr RA, Addison CL, Snider D, Muller WJ, Gauldie J, Graham FL. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNFalpha. Gene Ther 1997; 4:1181-8.
31. Soo Hoo W, Lundeen KA, Kohrumel JR, Pham NL, Brostoff SW, Bartholomew RM, Carlo DJ. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model. J Immunol 1999; 162:7343-9.
32. Ji J, Li J, Holmes LM, Burgin KE, Yu X, Wagner TE, Wei Y. Synergistic anti-tumor effect of glycosylphosphatidylinositol-anchored IL-2 and IL-12. J Gene Med 2004; 6:777-85. (Pubitemid 40228094)
33. Ji J, Li J, Holmes LM, Burgin KE, Yu X, Wagner TE, Wei Y. Glycoinositol phospholipid-anchored interleukin 2 but not secreted interleukin 2 inhibits melanoma tumor growth in mice. Mol Cancer Ther 2002; 1:1019-24.
34. Sonn CH, Yoon HR, Seong IO, Chang M-R, Kim YC, Kang H-C, et al. MethA Fibrosarcoma Cells Expressing Membrane-Bound Forms of IL-2 Enhance Antitumor Immunity. J Microbiol and Biotech 2006; 16:1919-27.
35. Chang MR, Lee WH, Choi JW, Park SO, Paik SG, Kim YS. Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2. Exp Mol Med 2005; 37:240-9.
36. Choi JW, Lim HY, Chang M-R, Cheon J-Y, Kim YS. Anti-tumor immunity induced by tumor cells expresing a membrane-bound form of IL-2 and SDF-1. Animal Cells and systems 2008; 12:193-201.
37. Chakrabarti R, Chang Y, Song K, Prud'homme GJ. Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA). Vaccine 2004; 22:1199-205.
38. Kim YS, Sonn CH, Paik SG, Bothwell AL. Tumor cells expressing membrane-bound form of IL-4 induce antitumor immunity. Gene Ther 2000; 7:837-43.
39. Cimino AM, Palaniswami P, Kim AC, Selvaraj P. Cancer vaccine development: protein transfer of membrane-anchored cytokines and immunostimulatory molecules. Immunol Res 2004; 29:231-40.
40. Nagarajan S, Selvaraj P. Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. Cancer Res 2002; 62:2869-74. (Pubitemid 34525773)
41. el-Shami KM, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines. J Interferon Cytokine Res 1999; 19:1391-401.
42. Kim YS. Tumor therapy applying membrane-bound form of cytokines. Immune network 2009; 9:158-68.
43. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and anti-metastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178:1223-30.
44. + alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J Immunol 1996; 156:3366-73.
45. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278:1623-6.
46. Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 2000; 60:3832-7.
47. Saudemont A, Buffenoir G, Denys A, Desreumaux P, Jouy N, Hetuin D, et al. Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia 2002; 16:1637-44.
48. Elzaouk L, Moelling K, Pavlovic J. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Exp Dermatol 2006; 15:865-74. (Pubitemid 44473325)